This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cramer's 'Mad Money' Recap: Biotech in the Spotlight

Click here for an archive of Cramer's "Mad Money" Recaps.


There is a tug of war for dollars on Wall Street this week. The tug of war is between technology and biotech. Technology won on Monday night. But Tuesday night belonged to biotech.

On the heel of Tuesday's news, the growth dollars are heading to biotech after Amgen (AMGN) and Gilead (GILD) reported great second-quarter numbers after the closing bell.

But Jim Cramer told his "Mad Money" viewers on CNBC that biotech will do especially well in the future -- especially if investors compare them with the Big Pharma stocks of today.

Investors also will be looking to put money to work in Genentech (DNA), Celgene (CELG) and Genzyme (GENZ). In fact, Cramer said, he never wants to hear about Pfizer (PFE) and Merck (MRK) again.

"We want to be looking for stocks that will be in our kids' medicine cabinets," he said. Pfizer and Merck have the stuff that is in cabinets today, he said.

What's more, Cramer said that Big Pharma doesn't innovate anymore. They just repackage stuff so that they can squeeze out every last dime. The biotech companies are the future of pharmaceuticals, he said.

"Get into biotech now to make money off of lifesaving drugs," Cramer concluded.

Motorola CEO Talk

Motorola (MOT) reported a great second quarter after the bell on Tuesday night. It reported better-than-expected earnings and sales. But the stock sold off after hours. Cramer talked with CEO Ed Zander about the quarter and about the company's future. Zander outlined a host of products that will continue to keep the momentum going at Motorola.

After chatting with Zander, Cramer said that the stock ran up in anticipation of great numbers. Cramer now thinks that the stock might pull back, however. And if it does, he said that he would definitely be a buyer. Cramer also pointed out that Motorola would be meeting with analysts next week to discuss business as well. Finally, if Motorola had reported its numbers by itself on Tuesday -- without Yahoo! (YHOO) and Lucent (LU) also reporting -- the stock would have been up on Tuesday night. Instead, it was down. Cramer believes weakness in Motorola stock is a gift, he said.

The 'Lightning Round'

Bullish

Cramer was bullish on: Gold Kist (GKIS), Schering-Plough (SGP), Homex (HXM), WCI Communities (WCI), Syneron Medical (ELOS), Apache (APA), SCP Pool (POOL), Chicago Mercantile (CME), Expeditors (EXPD), Allscripts Healthcare (MDRX), Titanium Metals (TIE), Orleans Homebuilders (OHB), BRE Properties (BRE), International Paper (IP), Microtune (TUNE), Logitech (LOGI), Novatel (NGPS).

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs